Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) Stock Soars After the Regulatory Approval of Lymphoaim in India
Winning regulatory approval can be a major boost for biopharmaceutical companies and hence, the Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) stock is in action during premarket trading period this morning. Trading Data On Monday, NAVB stock moved up 3% to $0.8860 with more than 79K shares, compared to its average volume of 84K shares. The stock moved within a range of $0.8600 – 0.8999 after opening trade at $0.86. Moreover, the stock…